Recognized in both pre-and post-approval pharmacovigilance operationsDURHAM, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced it has been recognized as a “Leader” for pharmacovigilance (PV) operations by Everest Group in its annual Pharmacovigilance Operations PEAK Matrix® Assessment 2025. Fortrea’s top position was recognized in both pre-and post-approval PV operations in Everest Group’s proprietary framework, which assess ...

Company Announcement - Fortrea will release its first quarter 2025 financial results on May 12, 2025, before the market opens [1] - A conference call will be held at 9:00 am ET on the same day to review the financial results and conduct a Q&A session [1] Participation Details - Participants can register for the earnings call online at the Fortrea Investor Relations website and are advised to join at least 10 minutes early to avoid delays [2] - A replay of the conference call will be available shortly after the event on the Fortrea Investor Relations website [2] Company Overview - Fortrea is a leading global provider of clinical development solutions to the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies [3] - The company offers phase I-IV clinical trial management, clinical pharmacology, and consulting services, leveraging over 30 years of experience across more than 20 therapeutic areas [3] - Fortrea operates in about 100 countries, providing focused and agile solutions to its customers globally [3]

Core Insights - Medpace (NASDAQ: MEDP) has experienced a significant share price decline of 35% over the past two and a half years [1] Company Overview - Medpace is a publicly traded company that has not been thoroughly researched since its initial discovery in 2022 [1] - The company is part of a broader investment strategy that includes a focus on identifying strong businesses at reasonable prices for long-term holding [1] Investment Perspective - The investor expresses a slight bias towards technology companies but maintains a diverse investment approach, including opportunities in crypto and global markets [1] - There is a beneficial long position in Medpace shares, indicating confidence in the company's potential [1]

Fortrea Holdings (FTRE) Q4 2024 Earnings Call March 03, 2025 09:00 AM ET Company Participants Hima Inguva - Head of Investor Relations & Corporate DevelopmentThomas Pike - CEO, President & ChairmanJill McConnell - Chief Financial OfficerPatrick Donnelly - Managing DirectorDavid Windley - Managing DirectorCharles Rhyee - Managing DirectorMichael Ryskin - Managing Director Conference Call Participants Justin Bowers - AnalystElizabeth Anderson - Senior Managing Director & Research AnalystLuke Sergott - Analyst ...